Drugs / MT-303
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06478693 | Jul 2024 → Dec 2027 expected | hepatocellular carcinoma | Myeloid Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT-303 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06478693 ↗ |
| Route | Intravenous | “Participants will receive MT-303 through intravenous infusion.” NCT06478693 ↗ |